Trial Profile
Phase I/II study of preoperative chemoradiotherapy with Gemcitabine and S-1 for resectable pancreatic cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Sep 2020
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Apr 2020 Planned End Date changed from 31 Aug 2014 to 31 Aug 2020.
- 19 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2013 Planned End Date changed from 1 Aug 2013 to 31 Aug 2014 as reported by University Hospital Medical Information Network - Japan record.